Zydus Cadila gets USFDA nod for antiviral ointment
Drug firm Zydus Cadila on Tuesday said it has received final nod from the US health regulator to market antiviral Acyclovir ointment in the American19-03-2019
19-03-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Acyclovir Ointment19-03-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Valsartan and Hydrochlorothiazide Tablets16-03-2019
Zydus Cadila gets USFDA nod to market generic anti-diabetic drug
Drug firm Zydus Cadila on Thursday said it has received tentative nod from the US health regulator to market generic Sitagliptin and Metformin Hydro14-03-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets14-03-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Potassium Chloride Extended-Release Capsules USP13-03-2019
Zydus Cadila gets USFDA nod to market blood pressure lowering drug
Drug firm Zydus Cadila Tuesday said it has received final approval from the US health regulator to market Atenolol and Chlorthalidone tablets USP, us12-03-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Atenolol and Chlorthalidone Tablets USP12-03-2019
Zydus Cadila gets USFDA nod for transdermal product
Drug firm Zydus Cadila on Tuesday said it has received nod from the US health regulator to market its Rivastigmine transdermal system, used for tre05-03-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives USFDA approval for its first transdermal product, Rivastigmine Transdermal System05-03-2019